As described in the CY 2026 OPPS/ASC proposed rule, we proposed to strengthen this requirement, beginning January 1, 2026, by replacing it with an attestation in the MRF, and that attestation would also contain new specifications (compared to existing affirmation requirements)
CONCLUSION Interest in optimal BPC 157 dosage continues to grow, but current research remains limited and there is no established therapeutic dosing standard for general use
The interstitial cystitis data base study group
[1] Methadone: (Moderate) Use caution when using dexpanthenol with drugs that decrease gastrointestinal motility, such as opiate agonists, as it may decrease the effectiveness of dexpanthenol
as with other incretin-based therapies, a modest increase in resting heart rate has been observed in early trials
4a,c), as well as changes in specific lipid species that were influenced by EtOH treatment (Fig